Assessment of Microorganisms and Host Response In Liver Diseases

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-70
SponsorUniversity of Aberdeen

About this trial

The normal human gut is home to millions of microbes including bacteria, fungi, and viruses, collectively forming the gut microbiota, which exists in harmony within us. Much research is still required to fully understand the contribution of microbes resident in the large intestine in liver diseases. The liver receives blood from the gut carrying all the necessary nutrients needed for our body but also has to deal with toxins derived from the microbes residing in the intestines. The gut microbiota is altered in liver disease. We still do not know clearly how this change impacts liver function and the health of liver patients. The purpose of our study is to answer this question by assessing the gut microbiota using modern microbiological and molecular methods. By studying the alterations in the gut microbiota in patients with liver disease we can understand how they affect our immune system and metabolism. This will help design novel medicinal products to prevent and treat liver disease.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Willing and able to provide informed consent

Definitive diagnosis of specific liver disease utilising clinical, biochemical, and radiological tests

Male or female aged between 18-70 years

Able to understand written or verbal information in English

Disqualifiers

Pregnancy and breastfeeding

Treatment with antibiotics in the last month

Treatment with steroids or immunosuppressive drugs in the last month

Regular consumption of over-the-counter prebiotics and probiotics from pharmacies or other retailers in the last month.

Trial population

Patients in clinics and wards in secondary care.

Trial design

Design model

Case-control

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

200 Participants
are grouped into 2 trial groups
Group A: Liver diseases
Group B: Control

Trial outcomes

Primary outcomes

1

To identify the bacterial, fungal, and virological agents present in patients with liver disease as opposed to controls

Microbiome analysis in liver patients and controls

Time frame
5 years

Secondary outcomes

1

To assess the host immune response against specific microbes isolated from patients with liver disease and controls

Immune response in liver patients and controls

Time frame
5 years
2

To characterise the changes in the liver immune microenvironment by analysing liver biopsies from patients

Liver biopsy analysis

Time frame
5 years

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: